Vote Scores

Home / Companies / Palvella Therapeutics, Inc. / 10 Jun 2026

Meeting · year to 30 June 2026281 filers reporting

Palvella Therapeutics, Inc.: meeting of 10 Jun 2026

Votes reported on Form N-PX, item by item

281 Form N-PX filers reported votes at the Palvella Therapeutics, Inc. meeting of 10 Jun 2026. Their records fall into 6 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

3 nominees; 80.9% of reported votes for; 55 filers withheld from or voted against at least one nominee.

513 vote records from 103 filers. 5 of the 102 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

94.2% for0.0% against5.8% other4.9% against management103 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

394 vote records from 279 filers. 21 of the 263 filers that marked the item either way voted against management. 16 filers reported this item without a management mark.

86.4% for6.5% against7.2% other8.0% against management279 filers98.6% for1.3% against0.1% other1.4% against management12,181,238 reported shares
3

SECTION 14A SAY-ON-PAY VOTESIssuer

Frequency of the say-on-pay vote

one year: 251 filers; for: 6 filers; three years: 3 filers; abstain: 2 filers; 1-year: 2 filers; none: 2 filers.

393 vote records from 279 filers. 4 of the 264 filers that marked the item either way voted against management. 15 filers reported this item without a management mark.

2.2% for0.0% against97.8% other1.5% against management279 filers14.9% for0.0% against85.1% other0.4% against management11,386,467 reported shares
4

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

171 vote records from 103 filers. 1 of the 102 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

98.1% for0.0% against1.9% other1.0% against management103 filers99.8% for0.0% against0.2% other0.2% against management3,013,029 reported shares
5

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

177 vote records from 105 filers. 63 of the 104 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

39.0% for59.0% against1.9% other60.6% against management105 filers56.7% for43.1% against0.2% other43.1% against management3,014,074 reported shares, counted once per item in this group
6

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

171 vote records from 103 filers. 65 of the 102 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

35.9% for62.1% against1.9% other63.7% against management103 filers52.2% for47.6% against0.2% other47.6% against management3,013,029 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors2. Say-on-pay3. Pay-vote frequency4. Auditor
VanguardForForSplit or no voteFor
BlackRock and iSharesForForSplit or no voteFor
FidelityForForSplit or no voteFor
DimensionalAbstain or withhold *ForSplit or no vote *For
State Street and SPDRForForSplit or no voteFor
Franklin TempletonForForSplit or no voteFor
InvescoForAgainst *Split or no voteFor
EquitableForForSplit or no voteFor
Charles SchwabForForSplit or no voteFor
Nuveen and TIAAForForSplit or no voteFor
ProShares and ProFundsForForSplit or no voteFor
John Hancock and ManulifeForForSplit or no voteFor
Morgan Stanley, Eaton Vance and CalvertAbstain or withhold *ForSplit or no voteFor
J.P. MorganNo reportForSplit or no voteNo report
Goldman SachsForForSplit or no voteFor
PGIM and PrudentialForForSplit or no voteFor
Jackson National fundsForForSplit or no voteFor
Northern Trust and FlexSharesSplit or no voteForSplit or no voteSplit or no vote
SEIForForSplit or no voteFor
T. Rowe PriceForForSplit or no voteFor
Lincoln FinancialForForSplit or no voteFor
VoyaForForSplit or no voteFor
Russell InvestmentsForForSplit or no voteFor
NationwideForForSplit or no voteFor
Victory CapitalForForSplit or no voteFor
Brighthouse FundsForForForFor
Guggenheim and RydexForForSplit or no voteFor
Columbia ThreadneedleForForSplit or no voteFor
BNY MellonNo reportForSplit or no voteNo report
PrincipalAbstain or withhold *ForSplit or no voteFor
Pacific Life fundsForForSplit or no voteFor
Global XForForSplit or no voteFor
MFSForForSplit or no voteFor
TransamericaForForSplit or no voteFor
Federated HermesForForSplit or no voteFor
AllianceBernsteinForForSplit or no voteFor
DWSForForSplit or no voteFor
Neuberger BermanForForSplit or no voteFor
Natixis and Loomis SaylesNo reportForSplit or no voteNo report
Artisan PartnersNo reportForSplit or no voteNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Palvella Therapeutics, Inc. meeting?

281 Form N-PX filers reported votes at the meeting of 10 Jun 2026. On say-on-pay, 21 of 263 voted against management (8.0%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Palvella Therapeutics, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Palvella Therapeutics, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Palvella Therapeutics, Inc. with a meeting date within three days of 10 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.